Background No studies have been conducted in the UK context to date that categorise medications in terms of appropriateness for patients with advanced dementia, or that examine medication use in these vulnerable patients. Objectives The objectives of this study were to categorise the appropriateness of a comprehensive list of medications and medication classes for use in patients with advanced dementia; examine the feasibility of conducting a longitudinal prospective cohort study to collect clinical and medication use data; and determine the appropriateness of prescribing for nursing home residents with advanced dementia in Northern Ireland (NI), using the categories developed. Methods A three-round Delphi consensus panel survey of expert clinicians was used to categorise the appropriateness of medications for patients with advanced dementia [defined as having Functional Assessment Staging (FAST) scores ranging from 6E to 7F]. This was followed by a longitudinal prospective cohort feasibility study that was conducted in three nursing homes in NI. Clinical and medication use for participating residents with advanced dementia (FAST scores ranging from 6E to 7F) were collected and a short test of dementia severity administered. These data were collected at baseline and every 3 months for up to 9 months or until death. For those residents who died during the study period, data were also collected within 14 days of death. The appropriateness ratings from the consensus panel survey were retrospectively applied to residents' medication data at each data collection timepoint to determine the appropriateness of medications prescribed for these residents. Results Consensus was achieved for 87 (90 %) of the 97 medications and medication classes included in the survey. Fifteen residents were recruited to participate in the longitudinal prospective cohort feasibility study, four of whom died during the data collection period. Mean numbers of medications prescribed per resident were 16.2 at baseline, 19.6 at 3 months, 17.4 at 6 months and 16.1 at 9 months. Fourteen residents at baseline were taking at least one medication considered by the consensus panel to be never appropriate, and approximately 25 % of medications prescribed were considered to be never appropriate. Post-death data collection indicated a decrease in the proportion of never appropriate medications and an increase in the proportion of always appropriate medications for those residents who died. Conclusions This study is the first to develop and apply medication appropriateness indicators for patients with advanced dementia in the UK setting. The Delphi consensus panel survey of expert clinicians was a suitable method of developing such indicators. It is feasible to collect information on quality of life, functional performance, physical comfort, neuropsychiatric symptoms and cognitive function for this subpopulation of nursing home residents with advanced dementia. (2015( ) 32:67-77 DOI 10.1007 Key Points This study is the first to develop medication appropriateness indicators for patients with advanced dementia in the UK setting.
medication use for participating residents with advanced dementia (FAST scores ranging from 6E to 7F) were collected and a short test of dementia severity administered. These data were collected at baseline and every 3 months for up to 9 months or until death. For those residents who died during the study period, data were also collected within 14 days of death. The appropriateness ratings from the consensus panel survey were retrospectively applied to residents' medication data at each data collection timepoint to determine the appropriateness of medications prescribed for these residents. Results Consensus was achieved for 87 (90 %) of the 97 medications and medication classes included in the survey. Fifteen residents were recruited to participate in the longitudinal prospective cohort feasibility study, four of whom died during the data collection period. Mean numbers of medications prescribed per resident were 16.2 at baseline, 19.6 at 3 months, 17.4 at 6 months and 16.1 at 9 months. Fourteen residents at baseline were taking at least one medication considered by the consensus panel to be never appropriate, and approximately 25 % of medications prescribed were considered to be never appropriate. Post-death data collection indicated a decrease in the proportion of never appropriate medications and an increase in the proportion of always appropriate medications for those residents who died. Conclusions This study is the first to develop and apply medication appropriateness indicators for patients with advanced dementia in the UK setting. The Delphi consensus panel survey of expert clinicians was a suitable method of developing such indicators. It is feasible to collect information on quality of life, functional performance, physical comfort, neuropsychiatric symptoms and cognitive function for this subpopulation of nursing home residents with advanced dementia.
Introduction
Advanced dementia is characterised by profound cognitive and functional impairment, inability to ambulate independently, urinary and faecal incontinence, and minimal verbal communication [1, 2] . Studies of medication use in populations with a reduced life expectancy, albeit not specific to patients with advanced dementia, have highlighted the prevalence of suboptimal and inappropriate medication use [3] [4] [5] [6] [7] [8] . Persons with advanced dementia are more likely to be subject to polypharmacy than healthier persons with a longer life expectancy and are at increased risk of inappropriate prescribing and adverse outcomes as a result of medication therapy [6, [9] [10] [11] . They are at greater risk of receiving overly aggressive care [12] , and often have a prolonged terminal phase in advanced disease [13] . They may experience a high level of symptoms including shortness of breath, constipation, febrile episodes, agitation and eating problems [1, [13] [14] [15] [16] [17] [18] [19] .
Medication use among patients with advanced dementia has been inadequately characterised to date. Most of the limited number of studies conducted in this area [15, [20] [21] [22] [23] have utilised prospective longitudinal cohort designs to describe medication use over time either as the key objective [15, 20, 21] or as part of a much wider study of end-oflife care of persons with advanced dementia [24] , although larger cross-sectional studies of medication use that are less geographically limited in their study populations are starting to appear in the published literature [2] . Appropriateness of prescribing was considered in a number of these studies, which focused on nursing home residents with advanced dementia nearing the end of life in the USA [2, 21, 22] , Italian patients with advanced dementia residing in long-term care institutions or at home [23] , and patients admitted to an acute geriatric unit in Spain [25] . The majority of these studies employed the classification system developed by Holmes et al. [21] , which categorised medications as never appropriate, rarely appropriate, sometimes appropriate or always appropriate for persons with advanced dementia in whom palliation of symptoms was the primary goal of therapy [2, [21] [22] [23] .
To the knowledge of the authors, no studies have been conducted in the UK context to date that categorise medication appropriateness for patients with advanced dementia who are nearing the end of life or that examine medication use by these vulnerable patients. The aims of this study were to develop such a classification system, examine the feasibility of conducting a longitudinal prospective cohort study to collect clinical and medication use data, and determine the appropriateness of prescribing for nursing home residents with advanced dementia in Northern Ireland (NI) using the system developed.
Methods

Delphi Consensus Panel
Physicians who were members of the Clinical Management Group of the Northern Ireland Clinical Research Network for Dementia (n = 9) were invited to participate in a consensus panel to rate medication appropriateness in persons with advanced dementia in whom palliation of symptoms is the primary goal of therapy. This panel is representative of specialists who provide care to patients with advanced dementia in the UK and includes geriatricians (n = 4) (one of whom specialises in pharmacology and therapeutics), old age psychiatrists (n = 4) and one neurologist.
A postal questionnaire was administered in a threeround Delphi process. In the first round (July 2011), participants were mailed a selection of literature regarding medication use in palliative care, a conceptual model regarding prescribing for patients late in life (to provide background information and to assist in the classification of medications into appropriateness categories [20, 21, 26, 27] ) and a questionnaire. The questionnaire collected demographic data and data regarding clinical practice pertaining to each participant, including age, sex, details of current job title, area of practice and percentage of typical working week spent in clinical practice. Participants were also asked to indicate their professional and personal experience in caring for persons with dementia nearing the end of life, using a scale from 1 (representing limited experience) to 10 (extremely experienced). Participants were asked if they had received training in palliative care, and, if so, whether this was delivered as part of a formal palliative care training programme. Participants were then asked to place the appropriateness of 85 medications and medication classes into one of four categories: never appropriate, rarely appropriate, sometimes appropriate or always appropriate for use in patients with advanced dementia. Medications were selected based on the classification system used in the British National Formulary (BNF) [28] , ensuring a rational organisation of medications into therapeutic classes. Participants were also given the opportunity to add any medications not included that they thought were important. Physicians were instructed to assume that the patients for whom they were assessing medication appropriateness had Functional Assessment Staging (FAST) scores ranging between 6E and 7F [29, 30] . This corresponds to patients who need assistance with bathing, dressing and toileting, and who have urinary and faecal incontinence (FAST 6E); who have minimal verbal ability (FAST 7A and 7B); who are unable to ambulate (FAST 7C), sit up (FAST 7D) or smile (FAST 7E); or who cannot hold their head up (FAST 7F). While patients with FAST scores of 6E may be considered to have moderately severe dementia, categorisation of the appropriateness of medications by the Delphi consensus panel included these patients to enable comparisons to be drawn with the system developed by Holmes et al. [21] , which included patients with FAST scores of 6E and above.
In the second and third rounds of the survey (January and July 2012, respectively), participants were mailed further copies of the questionnaire, which had been modified to remind them of their responses in the previous round and which contained an anonymous summary of all responses, including the most common response regarding appropriateness of each medication or medication class. Consistent with other Delphi methods and other studies [21, 31] , consensus for a medication or medication class was defined according to agreement on categorisation by at least 55 % of the respondents (corresponding to five of the nine physicians on the panel). This provided the opportunity to revise the medication appropriateness categorisations on the basis of the group's responses and aimed to increase consensus within each round. Any medication(s) for which consensus was achieved by 100 % of the respondents in a previous round was omitted from the questionnaire in the subsequent round. Each respondent was reimbursed £250 for their participation on completion of the three rounds of the survey. All responses to the final round were returned by January 2013.
Longitudinal Prospective Cohort Study
Nursing Home Recruitment
The feasibility study was conducted in three nursing homes in NI. Nursing homes with more than 30 resident beds (the average number of beds in a nursing home in NI) were eligible to participate; this included homes for general nursing category residents and those that provided specialised dementia care (n = 181). Based on the authors' knowledge of, and previous collaborative research programmes involving, nursing homes in NI, a convenience sample of three homes was selected. Written consent was obtained from the managers of these participating nursing homes. It was estimated that around one-third of residents would have advanced dementia (n = 10 per home) and of these, 50 % would participate (n = 5 per home), yielding a total sample size of 15 residents from three nursing homes, which was considered sufficient for this feasibility study.
Resident Recruitment
The recruitment process for eligible residents involved a number of stages. Nursing home managers identified residents with dementia and the members of nursing staff who provided most care to each of these residents on a regular basis (the residents' named nurse). Eligibility criteria for residents were as follows: (1) 60 years of age or older; (2) diagnosis of dementia; (3) FAST score between 6E and 7F; (4) resident in the nursing home for at least 30 days; and (5) not participating in any other research or studies. Eligibility criteria for named nurses were that the nurse was (1) regularly assigned to care for this resident; and (2) not participating in any other research or studies. As residents with advanced dementia lack decisional capacity, written informed assent from their next-of-kin or legal guardian was obtained to screen the resident for eligibility to participate and to examine medical records held by residents' primary care physicians [general practitioners (GPs)] to confirm a diagnosis of dementia. Written informed consent was also obtained from residents' named nurses to complete functional assessment staging of the resident using the FAST scale [29] . Upon confirmation of eligibility to participate, written assent was obtained from the residents' next-of-kin or legal guardians and written informed consent obtained from residents' named nurses for participation in the study. Where more than five residents were eligible for screening at each of the three homes and subsequently determined to be eligible, five were randomly selected to take part in the study.
Data Collection and Analysis
The following data were collected at baseline: nursing home characteristics, including ownership (private, statutory, voluntary, single home ownership, part of a chain of homes), number of nurses on staff, number of beds, type of care home (general nursing home, home offering specialised dementia care), location (rural or urban); number of general practices and GPs providing care to the nursing home; and extent of involvement of old-age psychiatry in the home. Other data were collected at baseline and every 3 months for up to 9 months or until death between October 2011 and September 2012, as detailed in Table 1 .
As the Delphi consensus panel survey was completed in January 2013, the appropriateness ratings from the consensus panel recommendations were applied retrospectively to each resident's medication data at each data collection timepoint to determine which of the residents' medications were never appropriate, rarely appropriate, sometimes appropriate or always appropriate. The feasibility of using the proposed approach to collect clinical data and data pertaining to medication use was also determined. Statistical analysis was descriptive.
Ethical and Governance Approvals
Ethical approval was obtained from the Office for Research Ethics Committees Northern Ireland (ORECNI). Research governance approval was obtained from the organisations employing the physicians who participated in the consensus panel survey.
Results
Delphi Consensus Panel Survey
All nine physicians (seven males and two females, mean age 45 years) from the Clinical Management Group of the Northern Ireland Clinical Research Network for Dementia agreed to participate in the consensus panel and completed the three rounds of the survey. Respondents spent an average of 86.6 % of their working week in clinical practice and the majority (n = 7) had received training in the delivery of palliative care; however, this was not always delivered as part of a formal training programme. All physicians, apart from one, rated themselves as highly experienced as a professional caring for persons nearing the end of life, with scores ranging from 4 to 10 (mean score for all participants = 8.33). Two physicians rated themselves as highly experienced in their personal lives in caring for persons with dementia nearing the end of life, with scores ranging from 1 to 10 (mean score for all participants = 6.43).
Increasing consensus regarding the appropriateness of medications and medication classes was achieved with each survey round. Twelve medications or medication classes not included in rounds 1 or 2 of the survey were considered important by the physicians and subsequently added. After round 3, consensus had been achieved for 87 (90 %) of the 97 medications and medication classes included in the survey. The complete list of medications and their appropriateness ratings as determined by the consensus panel are detailed in Table 2 .
Longitudinal Prospective Cohort Study
Nursing Home Characteristics
The three participating homes were privately owned with 40, 56 and 49 beds (average number of beds = 48). Only one home [nursing home (NH) 3] had an Elderly Mental Infirm (EMI) unit that provided specialist dementia care (n = 9 beds). There was involvement of an old age psychiatry team at all three homes (psychiatrists assessed and reviewed residents with dementia when required) and, on average, GPs from seven general practices provided care at each home (Table 3) .
Resident Characteristics
Three of the 33 eligible residents died before screening could take place and a number of next-of-kin did not return signed assent forms to allow screening to take place. Nine residents per home were screened for eligibility to participate and five residents were randomly selected.
Of the 15 residents recruited (average age 86 years), ten were female and five were male. Prior to nursing home admission, eight residents resided in their own home, two in a residential home, one in sheltered accommodation and one in another nursing home. The types of dementia documented (primarily from GP records) varied: six residents were diagnosed as having Alzheimer's disease, four were coded as having vascular dementia and two had multiple infarct dementia. Senile dementia was coded for two residents and one resident was diagnosed as having unspecified dementia. Mean duration of dementia was just under 6 years (71.4 months). Unadjusted Charlson co-morbidity scores ranged from 1 to 4, and age-adjusted scores ranged from 4 to 8. Four residents died during the study period (three before the 3-month data collection point and one before the 6-month data collection point); documented causes of death were bronchial pneumonia (n = 3) and a perforated bowel (n = 1). One resident was transferred to another nursing home.
FAST scores ranged from 6E (faecal incontinence) to 7D (could not sit up) at the four data collection points (Table 4) . Neuropsychiatric Inventory-Nursing Home version (NPI-NH) scores are also detailed at each data collection point in Table 4 ; the presence of behavioural disturbances varied greatly across the 15 residents recruited to the study, with each resident experiencing at least one of the ten behavioural disturbances occurring in dementia throughout the duration of the study. Caregiver distress scores, scores for cognitive function [using the short version of the Severe Impairment Battery (SIB-S)], quality of life [using the Quality of Life in late stage Dementia (QUALID) scale] and symptom management at the end of life [using the Symptom Management at the End of Life in Dementia (SM-EOLD) scale] are outlined in Table 4 .
Prevalence and Appropriateness of Medication Use
Mean numbers of medications prescribed per resident were 16.2 at baseline, 19.6 at 3 months, 17.4 at 6 months and 16.1 at 9 months. This included regular and when-required medications, topical and ophthalmic preparations, and nutritional supplements.
The numbers of medications prescribed in each appropriateness category are summarised in Table 5 . At baseline, approximately one-quarter of the medications prescribed for residents were considered by the consensus panel to be never appropriate. Fourteen of the 15 participating residents were prescribed at least one of these medications. Use of medications classified as never appropriate by the consensus panel did not change significantly as the study progressed. Similarly, the percentage of medications classified as always appropriate remained stable over the period of data collection, ranging from 16.9 % at baseline to 15.1, 18.1 and 18.4 % at 3, 6 and 9 months, respectively. The post-death data collection indicated that there was a decrease in the proportion of never appropriate medications (12.0 %) and an increase in the proportion of always appropriate medications (28.0 %) for those residents who died during the study period.
This study utilised Delphi methodology to develop a classification system for the appropriateness of prescribing for patients with advanced dementia nearing the end of life. This method was selected as it involves sequential anonymous postal questionnaires interspersed by controlled feedback, and seeks to gain the most reliable consensus of opinion of a group of experts [39] . Furthermore, the avoidance of face-to-face interaction between group members prevents bias as each panel member is able to express their own opinions away from peer pressure [40] . Categorisation of medication appropriateness showed similarities to the classification system developed by Holmes et al. [21] , in which consensus was achieved for 69 (85 %) of the 81 included medications and medication classes. In the present study, consensus was achieved for a similar proportion of medications and medication classes (90 %) despite the slightly higher number of medications and medication classes included (n = 97). There were, however, some notable differences; in the classification system developed by Holmes et al. [21] , no consensus was achieved for aspirin, iron, vitamins, mineral supplements or finasteride, while in the present study, these medications were classified as never appropriate. Holmes et al. [21] classified acetylcholinesterase inhibitors and N-methyl-Daspartate receptor antagonists (memantine) as never appropriate; the consensus among the physicians in the present study was that these agents were rarely appropriate and sometimes appropriate, respectively. Furthermore, there were some medications, namely expectorants and tricyclic antidepressants, for which classifications of appropriateness varied widely. This variation may in part be explained by cross-national or cultural differences in prescribing in US and UK jurisdictions, but may also reflect the complexity and variability in decision making regarding medication use at the end of life for patients with advanced dementia and the lack of evidence-based guidance available to guide clinical practice [8, 27, 41] . FAST scores for participating residents ranged from 6E to 7D during the data collection period. Residents with FAST scores of 6E (n = 4) were in the less advanced stages of the disease, had higher scores on the SIB-S and better quality of life than residents with FAST scores of 7A and above. In the Delphi consensus process, physicians categorised the appropriateness of medications for use in patients with advanced dementia with FAST scores ranging between 6E and 7F. A recent study by Toscani et al. [23] examined the appropriateness of prescribing for Italian patients with advanced dementia residing in long-term care institutions and at home using the classification system developed by Holmes et al. [21] . In this study, patients with a FAST score of C7 were enrolled, but the authors reported data on patients with FAST scores of C7C as they argued that these patients had advanced dementia for which palliative care was clearly appropriate. However, the classification system developed by Holmes et al. [21] determined medication appropriateness in the context of providing care to patients with moderate to severe dementia approximating FAST stages 6E, 7A, 7B and 7C, and the authors recognised that the criteria on appropriateness of some medications may require reconsideration in the view of the advanced stage of dementia among the participants [23] . In terms of the eligibility criteria for a subsequent extension of the present feasibility study to a larger study, inclusion of patients with FAST scores of 7A and above should be considered, although this may require the validation of the Delphi consensus panel recommendations for such patients and may have an impact on the number of eligible residents from which to recruit. Other researchers have utilised a Global Deterioration Scale (GDS) of 7 (characterised by profound memory deficits, minimal or no verbal communication, urinary and faecal incontinence, and inability to walk) to define advanced dementia [1, 24] . A recent study by Molist Brunet et al. [25] used a combination of three measures to identify patients with advanced dementia: an inability to complete activities of daily living [defined by a Barthel index B30/100), incontinence and difficulty recognising family members (defined as a GDS of C6 in the case of Alzheimer-type dementia)], while Tjia et al. [2] used a Cognitive Performance Score (CPS) of 5 or 6 and the Minimum Data Set (MDS) diagnosis of dementia [2] . There is a recognition in the literature that the criteria used to define advanced dementia vary between studies, and that a consistent definition that can be applied both in clinical practice and in research, and in a standardised manner, is required [42] . This should be considered in the design of any future study in nursing homes in the NI or UK contexts.
It is well-acknowledged that dementia is associated with chronic co-morbidities [23, 42, 43] , and the findings from the present study, in which age-adjusted Charlson co-morbidity scores ranged from 4 to 8, corroborate this. Although numbers recruited to this feasibility study were small, it has highlighted the number of patients with lack of specificity in their diagnosis of dementia; this is recognised to be an issue particularly because treatment and prognosis may differ substantially based on the differential diagnosis [44] .
The mean numbers of medications prescribed per resident at each data collection point were similar to the mean number of medications prescribed per resident in the CareAD (Care of Nursing Home Residents with Advanced Dementia) study [20] , in which patients were prescribed a mean of 14.6 medications. Other studies have reported lower numbers of medications per resident ranging from a median of four medications [23] to means of 5.9, 6.5 and 7.3 medications per person [21, 22, 25] . However, this may in part be explained by the differences in medications included in and excluded from the analysis in each study.
Examination of the appropriateness of prescribing for residents using the Delphi consensus panel ratings revealed that 14 of the 15 residents at baseline were taking at least one medication considered by the consensus panel to be never appropriate, and that a significant proportion of medications (approximately one-quarter) prescribed were considered to be never appropriate. These figures are higher than those reported in previous studies [2, [21] [22] [23] , but do provide further evidence to support the conclusions of Tjia et al. [2] in their recent publication that ''most nursing home residents with advanced dementia receive medications of questionable benefit''. Variations in the prevalence reported in these studies may be explained by the differences in medications included in and excluded from the analysis in each study; for example, in the study by Tjia et al. [22] , drugs prescribed on a when-required basis, topical preparations, vitamins (with the exception of vitamin D) and antimicrobials were not included, whereas in the present study, regular and when-required medications, antimicrobials, topical and ophthalmic preparations, and nutritional supplements were included. Further, in the classification system developed by Holmes et al. [21] and utilised in the studies by Tjia et al. [2, 22] and Toscani et al. [23] , no consensus was achieved for aspirin, iron, vitamins, mineral supplements or finasteride, while in the present study these medications were classified as never appropriate.
Prescribing of medications classified as never appropriate did not change significantly as the study progressed. Similarly, the percentage of medications classified as always appropriate remained stable over the period of data collection. The post-death data collection indicated that there was a decrease in the proportion of never appropriate medications and an increase in the proportion of always appropriate medications for those residents who died during the study period. This is noteworthy despite the small number of residents involved; it may suggest a move away from curative goals of therapy towards palliative management of symptoms, as has been observed in other studies [3, 20, 21, 45] .
This study is the first to develop indicators for, and to report prevalence of, appropriate medication use in patients with advanced dementia nearing the end of life in the UK setting. There are, however, some limitations to this study that must be acknowledged. The Delphi consensus panel took significantly longer to complete than had been originally anticipated. This may have been due in part to the length of the survey, which required classification of 97 medications/medication classes into appropriateness categories. In order to facilitate the completion of any further consensus panel survey in an expeditious manner, administration via other methods such as a face-to-face meeting or online distribution could be considered. Furthermore, a larger representative consensus panel comprising physicians from a range of locations, clinical specialities and settings is required to extend the generalisability and scope of these findings. Numbers recruited to this feasibility study were small, and the ability to draw generalisable conclusions is limited. Although a number of residents with FAST scores of between 7B and 7E (severely demented) were unable to complete the short version of the SIB-S, use of this scale enabled assessment of cognitive function in residents who had such advanced dementia that they would have been unable to complete any other test of cognitive function. Future larger-scale studies should therefore continue to utilise the SIB-S to measure cognitive function. Previous work undertaken by Garfinkel and colleagues [46, 47] has reported that medication discontinuation using a geriatric-palliative approach and algorithm has favourable effects on mortality and morbidity, and lends support to further work developing and evaluating measures of medication appropriateness for older people with advanced dementia to provide an evidence base for rationalisation of prescribing in this vulnerable patient group.
Despite the limitations identified, the Delphi consensus panel survey was a suitable method of gaining consensus among expert clinicians on appropriateness of medications. The study findings demonstrate the feasibility of collecting information from medical records, from researcher-conducted interviews with residents' named nurses and from a researcher assessment of cognitive function using the SIB-S. This three-staged approach to data collection would therefore be suitable for use in a larger study.
Conclusion
This study is the first to develop and apply indicators for medication appropriateness for patients with advanced dementia nearing the end of life in the UK setting. It demonstrates the feasibility and suitability of utilising a Delphi consensus panel of experts to classify the appropriateness of medications for use in patients with advanced dementia. Data collection indicated that it is feasible to collect information on quality of life, functional performance, physical comfort, neuropsychiatric symptoms and cognitive function for nursing home residents with advanced dementia who are nearing the end of life.
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